PURPOSE:To assess anti-inflammatory effect of inhaled cyclosporine nanoparticles in the histology of a rodent model of asthma.
METHODS:A total of 16 mice were injected intraperitoneally with 10% ovalbumin on days 1 and 14 and on day 28 they were allocated to 2 treatment groups: 8 mice received 72 mg of inhaled cyclosporine nanoparticles diluted in lecithin and 8 received inhaled normal saline (placebo). These were compared to 5 controls. Following the treatment, all groups except the controls, were exposed to 10% nebulized ovalbumin followed by lung harvesting 24 hours later. Airway inflammation was graded for severity in a blinded fashion with an inflammation score of 0 to 3 with 0-normal, 1-mild, 2-moderate and 3-severe inflammation.
RESULTS:The mean inflammation scores were: inhaled normal saline (placebo) 2.25±0.25, inhaled cyclosporine nanoparticles 0.62±0.21 and control group 0. Cyclosporine had significantly lower inflammatory scores compared to placebo (0.62 and 1.81 respectively versus 0; p< 0.0001, 95% confidence interval).
CONCLUSION:This pilot study suggests that specific targeting of T-cells with inhaled anti-inflammatory agents such as cyclosporine control the inflammatory component of bronchial asthma. Future studies are needed in order to test efficacy and safety of this formulation as anti-inflammatory agents in asthma.
CLINICAL IMPLICATIONS:Inhaled cyclosporine can be used as an additional agents to contol asthma.
DISCLOSURE:Juan Sanchez, No Financial Disclosure Information; No Product/Research Disclosure Information